You have been asked if you would like to participate in the SAFE-D clinical research study because you have recently been diagnosed with type 2 diabetes and this is a risk factor for pancreatic cancer. A new blood test, developed by the biotechnology company ClearNote Health, aims to detect the presence of pancreatic cancer in the blood when it is at an early more treatable stage.
Help us improve early pancreatic cancer detection to save lives
Inclusion Criteria
- 50 – 84 years of age
- Recently diagnosed with type 2 diabetes (within the last 6 months and haemoglobin A1c (HbA1c) ≥ 48 or 6.5%)
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI scan (or CT scan if MRI is contraindicated)
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria
- Prior type 1 or type 2 diabetes diagnosis > 6 months
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for pancreatic cancer / pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- Current chronic or acute oral or systemic steroid use within 3 months of initial HbA1c or diabetes diagnosis
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis